The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
about
Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction.Advances and challenges in cirrhosis and portal hypertension.Biology of portal hypertension.
P2860
The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The anticoagulant rivaroxaban ...... vating hepatic stellate cells.
@en
The anticoagulant rivaroxaban ...... vating hepatic stellate cells.
@nl
type
label
The anticoagulant rivaroxaban ...... vating hepatic stellate cells.
@en
The anticoagulant rivaroxaban ...... vating hepatic stellate cells.
@nl
prefLabel
The anticoagulant rivaroxaban ...... vating hepatic stellate cells.
@en
The anticoagulant rivaroxaban ...... vating hepatic stellate cells.
@nl
P2860
P50
P356
P1433
P1476
The anticoagulant rivaroxaban ...... ivating hepatic stellate cells
@en
P2093
Erica Lafoz
Jaume Bosch
P2860
P304
P356
10.1002/HEP.29084
P407
P50
P577
2017-05-02T00:00:00Z